Shanghai Haohai Biological Technology Co's EBIT per Share for the
three
months ended in Mar. 2026 was €0.05.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.06.
During the past 12 months, the average EBIT per Share Growth Rate of Shanghai Haohai Biological Technology Co was -58.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 14.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 22.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -0.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
FRA:5HB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -35.2 Med: 9.2 Max: 50
Current: 14.3
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Shanghai Haohai Biological Technology Co was 50.00% per year. The lowest was -35.20% per year. And the median was 9.20% per year.
FRA:5HB's 3-Year EBIT Growth Rate is ranked worse than 51.75% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs FRA:5HB: 14.30
Shanghai Haohai Biological Technology Co (FRA:5HB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Shanghai Haohai Biological Technology Co EBIT per Share Related Terms
Shanghai Haohai Biological Technology Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co EBIT per Share Chart
Shanghai Haohai Biological Technology Co Annual Data
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co (FRA:5HB) has a EBIT per Share of €0.06 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Shanghai Haohai Biological Technology Co and its competitors. According to the industry distribution chart, Shanghai Haohai Biological Technology Co ranks #607 out of 1173 companies in the Biotechnology industry, placing it in the top 51.7%.
Is Shanghai Haohai Biological Technology Co's EBIT per Share too high?
Shanghai Haohai Biological Technology Co's current EBIT per Share is €0.06. Based on the distribution chart, Shanghai Haohai Biological Technology Co ranks #607 out of 1173 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Haohai Biological Technology Co ranks #607 out of 1173 companies for EBIT per Share. This places Shanghai Haohai Biological Technology Co in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Shanghai Haohai Biological Technology Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haohai Biological Technology Co's current EBIT per Share is €0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (FRA:5HB) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.63, compared to a current price of €1.75 — trading 33.5% below its estimated fair value. The current EBIT per Share is €0.06. Shanghai Haohai Biological Technology Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current EBIT per Share is €0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued.
The current stock price of €1.75 is trading 33.5% below its estimated GF Value™ of €2.63.
GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.
Key valuation signals for FRA:5HB:
EBIT per Share: €0.06
GF Value™: €2.63 vs. price of €1.75 (33.5% below fair value)
No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haohai Biological Technology Co Business Description
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
66GF Score
Get the complete analysis for FRA:5HB
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HB has been successfully added to your 
